Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI

Heidelberg, Germany – April 24, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3).

The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma.

Scientific posters supported by Novaliq will include:
“Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schmidl D., Werkmeister R., Adzhemian N., Kosobokovs S., Krösser S., Schmetterer L. Poster presentation on Sunday, April 29, 3:15-5:00 PM; Poster Board: B0119

“Ocular and Systemic Distribution of 14C- Perfluorohexyloctane following Topical Ocular Administration to Rabbits.”
Authors: Krösser S., Spencer E., Grillenberger R., Struble C., Eickhoff K.
Poster presentation on Tuesday, May 1, 8:15-10:00 AM; Poster Board: A0383

“Evaluating the lubricating effect of semifluorinated alkanes on the ocular surface.”
Authors: Agarwal P., Khun D., Krösser S., Eickhoff K., Wells F. S., Willmott G. R., Craig J. P., Rupenthal I. D.
Poster presentation on Tuesday, May 1, 11:15-13:00 AM; Poster Board: C0076

“The pharmacodynamic effect of LatanoSol eye drops on IOP of normotensive dogs.”
Authors: Eickhoff K., Prusakiewicz J., Uhlmann L., Struble C., Löscher F., Krösser S.
Poster presentation on Tuesday, May 1, 8:15-10:00 AM; Poster Board: B0037

We are proud to share and discuss the scientific data on our innovative and water-free platform technology with researchers, clinicians, and industry,” said Sonja Krösser, PhD, VP Preclinical and Clinical Development, Novaliq. “Our dedication to science is the basis for advancing our unique pipeline and developing innovative products that help physicians better serve their patients.

The Novaliq team will be available at ARVO 2018 in Honolulu, HI to discuss the research and to answer questions.
To arrange a meeting, please send an email to event@novaliq.com with day and time preference.

Novaliq Announces Positive Topline Results for Second Phase 3 Trial (Essence-2) of CyclASol® in Dry Eye Disease

Heidelberg, Germany, and Cambridge, MA, USA, December 21, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED).

Phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) conducted by Jiangsu Hengrui Pharmaceuticals in the People’s Republic of China shows statistically significant topline results

Heidelberg, Germany, and Cambridge, MA, USA, December 16, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) conducted by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) (SSE: 600276) in the People’s Republic of China showing statistically significant topline results compared to 0.6% sodium chloride solution.1

Novaliq receives EU Quality Management Certificate according to new Medical Device Regulation (MDR)

Heidelberg, Germany, October 12, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that it has implemented and applies a quality management system in accordance with Annex IX, Chapter I of the EU Medical Device Regulation (MDR), for conformity assessment of its medical devices NovaTears®, NovaTears®+Omega-3 and EvoTears™ OMEGA.

Bausch + Lomb announces statistically significant Topline Results from the Second Phase 3 Trial of NOV03 (perfluorohexyloctane) in Dry Eye Disease associated with Meibomian Gland Dysfunction

LAVAL, QC and HEIDELBERG, Germany, Sept. 30, 2021 – Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The companies announced statistically significant topline data from the first Phase 3 trial (GOBI trial) in April 2021.

Novaliq Completes Enrollment of Second Phase 3 Study for CyclASol® for the Treatment of Dry Eye Disease

Heidelberg, Germany, and Cambridge, MA, August 10, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the second of two Phase 3 (ESSENCE-2) studies, evaluating the investigational drug CyclASol® to treat the signs and symptoms of dry eye disease DED, has been completely enrolled with a total of 834 participants.